Latest News

Araris Biotech closes $24m Series A financing round

Araris’ linker technology enables site-specific payload attachment to a specific amino acid (Q295) within the IgG-Fc framework. When a payload is attached to this site, the antibody still maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong peptide bond resulting in exceptional stability in the blood stream and thus minimal adverse effects. © Araris Biotech AG


by tg

Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.

The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular Lymphoma Innovation and from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine. Proceeds from the financing will be used to support the further development and advancement of Araris’ preclincial antibody-drug conjugate (ADC) candidates, created using the company’s proprietary linker technology.

Araris Biotech AG’s inker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

Novo Nordisk Foundation funds Plant2Food with €27m

The focus of Plant2Food is to create a library of fundamental knowledge about the properties of plants and how they could replace food products that...

EU Health Union ignoring cardiology

While the EU has already presented rules to establish a European Health Data Space (EHDS) and Europe’s Plan against Cancer within its Medicines...

Amgen wins race of top `22 deals with $26bn for Horizon thx

Horizon confirmed Amgen's interest in a press release. The American group is to offer around $116.5 for each share. The offer price is about 20...

Vésale Bioscience wins R&D grant

Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...

CatalYm GmbH raises €50m to push visugromab development

Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...

A ray of hope in leukaemia

In 2021, Alyssa, a 13-year-old girl from Leicester, after a long struggle with what her family thought to be colds, viruses, and general tiredness,...

Standing Ovation inks exlusive partnership with Bel Group

Just one month after Standing Ovation SA won the start-up pitch at INDUSTRIA BIOTEC and got a €16m Series A financing, the two-year old company has...